Literature DB >> 18621409

Human herpesvirus-6 infection induces the reorganization of membrane microdomains in target cells, which are required for virus entry.

Huamin Tang1, Akiko Kawabata, Masaya Takemoto, Koichi Yamanishi, Yasuko Mori.   

Abstract

Cell-membrane raft microdomains are important for successful infection by several viruses. However, their role in the cell-entry process of human herpesvirus-6 (HHV-6) is unknown. Here we tested whether HHV-6 requires cell-membrane rafts for its entry. When cell-membrane rafts were disrupted by cholesterol depletion, target-cell entry by HHV-6 was inhibited, although the virus bound normally to the cells. HHV-6 infectivity was partially rescued by adding exogenous cholesterol. Interestingly, the HHV-6 cellular receptor, CD46, was found in the rafts after virus attachment, but not in the rafts of uninfected cells, indicating that HHV-6 infection induces the re-location of its receptor into the rafts. Furthermore, glycoprotein Q1, part of a viral glycoprotein complex that binds CD46, was also associated with rafts immediately after infection. These data suggest that cellular-membrane lipid rafts are important in viral entry and that HHV-6 may enter the target cells via the rafts.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18621409     DOI: 10.1016/j.virol.2008.05.028

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  20 in total

Review 1.  CD46 processing: a means of expression.

Authors:  Siobhan Ni Choileain; Anne L Astier
Journal:  Immunobiology       Date:  2011-07-13       Impact factor: 3.144

2.  Avidity binding of human adenovirus serotypes 3 and 7 to the membrane cofactor CD46 triggers infection.

Authors:  Hung V Trinh; Guillaume Lesage; Venus Chennamparampil; Benedikt Vollenweider; Christoph J Burckhardt; Stefan Schauer; Menzo Havenga; Urs F Greber; Silvio Hemmi
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

Review 3.  CD46 plasticity and its inflammatory bias in multiple sclerosis.

Authors:  Siobhan Ni Choileain; Anne L Astier
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2011-01-26       Impact factor: 4.291

4.  Cholesterol-rich microdomains as docking platforms for respiratory syncytial virus in normal human bronchial epithelial cells.

Authors:  Homero San-Juan-Vergara; Viviana Sampayo-Escobar; Niradiz Reyes; Byeong Cha; Lisandro Pacheco-Lugo; Terianne Wong; Mark E Peeples; Peter L Collins; Maria Eugenia Castaño; Shyam S Mohapatra
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

5.  The Neutralizing Linear Epitope of Human Herpesvirus 6A Glycoprotein B Does Not Affect Virus Infectivity.

Authors:  Aika Wakata; Satoshi Kanemoto; Huamin Tang; Akiko Kawabata; Mitsuhiro Nishimura; Chyntia Jasirwan; Nora Fahmy Mahmoud; Yasuko Mori
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

Review 6.  Lipids and membrane microdomains in HIV-1 replication.

Authors:  Abdul A Waheed; Eric O Freed
Journal:  Virus Res       Date:  2009-04-19       Impact factor: 3.303

7.  The Reorientation of T-Cell Polarity and Inhibition of Immunological Synapse Formation by CD46 Involves Its Recruitment to Lipid Rafts.

Authors:  Mandy J Ludford-Menting; Blessing Crimeen-Irwin; Jane Oliaro; Anupama Pasam; David Williamson; Natalie Pedersen; Patricia Guillaumot; Dale Christansen; Serge Manie; Katharina Gaus; Sarah M Russell
Journal:  J Lipids       Date:  2011-01-20

8.  Function of membrane rafts in viral lifecycles and host cellular response.

Authors:  Tadanobu Takahashi; Takashi Suzuki
Journal:  Biochem Res Int       Date:  2011-12-07

9.  y Human herpesvirus 6 envelope components enriched in lipid rafts: evidence for virion-associated lipid rafts.

Authors:  Akiko Kawabata; Huamin Tang; Honglan Huang; Koichi Yamanishi; Yasuko Mori
Journal:  Virol J       Date:  2009-08-19       Impact factor: 4.099

10.  Features of Human Herpesvirus-6A and -6B Entry.

Authors:  Takahiro Maeki; Yasuko Mori
Journal:  Adv Virol       Date:  2012-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.